Novartis AG has appointed John Tsai as head of global drug development (GDD) and chief medical officer, effective May 1. He will be based in Basel, Switzerland, will report to CEO Vas Narasimhan, and become a member of the executive committee. Tsai joins from Amgen Inc. where he has been chief medical officer and senior vice president of global medical since May 2017. He succeeds Narasimhan who became CEO of Novartis on Feb. 1. Rob Kowalski, who has led GDD ad interim since Feb. 1, will resume his responsibilities as head of global regulatory affairs for GDD.
GlaxoSmithKline PLC has appointed Kevin Sin as senior vice president and head of worldwide business development for pharmaceuticals research...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?